Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02788019 · ClinicalTrials.gov registry record · Phase 4

Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?

A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.

Terminated
Registry status
Phase 4
Development phase
52
Enrollment target

NCT02788019 is a Phase 4 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 52 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02788019, a Phase 4 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.

TERMINATED
Registry status
Phase 4
Development phase
52 participants
Enrollment target

Study Summary

This is a randomized noninferiority interventional study to determine the equivalence of two adductor canal block (ACB) methods: mid-thigh and distal thigh in patients undergoing medial foot, medial ankle, or medial leg surgery. Sixty eight patients will be identified during their orthopedic presurgical clinic visit, anesthesia preoperative clinic visit or Day Surgery Unit (Zale Lipshy Hospital, Clements University Hospital, and University of Texas Southwestern Outpatient Surgery Center) for eligibility. Eligible individuals may be introduced to the study in the orthopedic presurgical clinic or the anesthesia preoperative clinic by staff. After consent patients will be randomized (break-seal method) to receive either a mid-thigh or distal thigh block using ropivacaine prior to foot, ankle, or leg surgery. The following measurements will be obtained to determine the change in sensory distribution: pinprick test with Neuropen, maximum voluntary isometric contraction before and after block, postoperative pain scores (24 hrs and at discharge) and postoperative opiate consumption.

Interventions

  • DRUG Ropivacaine

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2016-05-26
Est. Completion 2020-03-23
Phase Phase 4

What the Registry Record Tells You About NCT02788019

The ClinicalTrials.gov registry entry for NCT02788019 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ropivacaine is the first listed.

NCT02788019 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02788019 about?

NCT02788019 is a clinical study titled "Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?". This is a randomized noninferiority interventional study to determine the equivalence of two adductor canal block (ACB) methods: mid-thigh and distal thigh in patients undergoing medial foot, medial ankle, or medial leg surgery. Sixty eight patients will be identified during their orthopedic presurg...

What is the current status of trial NCT02788019?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2016-05-26. Estimated completion is 2020-03-23.

What interventions are being tested in trial NCT02788019?

The interventions under investigation include: Ropivacaine (DRUG).

Who is sponsoring clinical trial NCT02788019?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.